Clinical and laboratory characteristics of 114 patients with myelofibrosis with myeloid metaplasia at the time of bone marrow study for angiogenesis
| Clinical parameters . | n . | Values . |
|---|---|---|
| Age | 114 | Median, 65.9 y (range, 29.7-92 y) |
| Sex | ||
| Males | 62 | 54.4% |
| Females | 52 | 45.6% |
| Type of MMM | ||
| AMM | 86 | 75.4% |
| PPMM | 18 | 15.8% |
| PTMM | 10 | 8.8% |
| Palpable spleen size below the left costal margin (in patients with intact spleen) | 109 | Median, 7 cm (range, 0-32 cm) |
| Peripheral blood count | 114 | Median (range) |
| Hemoglobin | 10.3 g/dL (5.7-17.2) | |
| White blood cell count | 9.1 × 109/L (1.1-125.7) | |
| Platelet count | 175 × 109/L (3-1580) | |
| Circulating blasts | 0.5% (0-24.5) | |
| Red cell transfusion dependency | ||
| Yes | 38 | 33.3% |
| No | 76 | 66.7% |
| Dupriez score | ||
| 0 | 46 | 40.4% |
| 1 | 48 | 42.1% |
| 2 | 20 | 17.5% |
| Presence of ascites | ||
| Yes | 13 | 11.7% |
| No | 101 | 88.3% |
| Bone marrow cellularity | 114 | Median, 70% (range, 5-100%) |
| Reticulin fibrosis grade | 99 | |
| ≤1 | 9 | 9% |
| 2 | 25 | 25% |
| 3 | 50 | 51% |
| 4 | 15 | 15% |
| Megakaryocyte clumping | 114 | |
| ≤ + 1 | 30 | 26.3% |
| + 2 | 41 | 36.0% |
| + 3 | 43 | 37.7% |
| Osteosclerosis grading | 114 | |
| 0 (Absent) | 65 | 57% |
| 1 | 32 | 28% |
| 2 | 17 | 15% |
| Bone marrow cytogenetic studies | 85 | |
| Normal | 34 | 41.5% |
| Trisomy 8 | 10 | 11.7% |
| 13q- | 10 | 11.7% |
| 20q- | 8 | 9.5% |
| Other abnormalities | 23 | 25.6% |
| Clinical parameters . | n . | Values . |
|---|---|---|
| Age | 114 | Median, 65.9 y (range, 29.7-92 y) |
| Sex | ||
| Males | 62 | 54.4% |
| Females | 52 | 45.6% |
| Type of MMM | ||
| AMM | 86 | 75.4% |
| PPMM | 18 | 15.8% |
| PTMM | 10 | 8.8% |
| Palpable spleen size below the left costal margin (in patients with intact spleen) | 109 | Median, 7 cm (range, 0-32 cm) |
| Peripheral blood count | 114 | Median (range) |
| Hemoglobin | 10.3 g/dL (5.7-17.2) | |
| White blood cell count | 9.1 × 109/L (1.1-125.7) | |
| Platelet count | 175 × 109/L (3-1580) | |
| Circulating blasts | 0.5% (0-24.5) | |
| Red cell transfusion dependency | ||
| Yes | 38 | 33.3% |
| No | 76 | 66.7% |
| Dupriez score | ||
| 0 | 46 | 40.4% |
| 1 | 48 | 42.1% |
| 2 | 20 | 17.5% |
| Presence of ascites | ||
| Yes | 13 | 11.7% |
| No | 101 | 88.3% |
| Bone marrow cellularity | 114 | Median, 70% (range, 5-100%) |
| Reticulin fibrosis grade | 99 | |
| ≤1 | 9 | 9% |
| 2 | 25 | 25% |
| 3 | 50 | 51% |
| 4 | 15 | 15% |
| Megakaryocyte clumping | 114 | |
| ≤ + 1 | 30 | 26.3% |
| + 2 | 41 | 36.0% |
| + 3 | 43 | 37.7% |
| Osteosclerosis grading | 114 | |
| 0 (Absent) | 65 | 57% |
| 1 | 32 | 28% |
| 2 | 17 | 15% |
| Bone marrow cytogenetic studies | 85 | |
| Normal | 34 | 41.5% |
| Trisomy 8 | 10 | 11.7% |
| 13q- | 10 | 11.7% |
| 20q- | 8 | 9.5% |
| Other abnormalities | 23 | 25.6% |
AMM, agnogenic myeloid metaplasia; PPMM, postpolycythemic myeloid metaplasia; PTMM, post-thrombocythemic myeloid metaplasia.